spacer
home > pmps > Winter 2003
PUBLICATIONS

Pharmaceutical Manufacturing and Packing Sourcer

pmps
Winter 2003
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. PMPS provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of PMPS
   
Text
PDF
Industry Insight 
In her Editor's Letter, Dr Patricia Lobo reviews the articles in this issue of PMPS  
view
bullet
Packaging, Packing & Anti-Counterfeiting
Are the right patients receiving the right drugs in the right dosage at the right time? Eric Tjoa, CEO at Tjoapack BV, reveals all in The Ultimate Solution for Reducing Medication Errors  
view
Phil Donaldson, Director of Sales and Marketing at the ALS Group, offers an insight into labelling developments, in Labelling Trends Expand Market Opportunities  
view
In Trends in Pharmaceutical Packaging, Bernard C Fenner, Head of Marketing at SIG Pack Systems, looks at future developments in the pharmaceutical sector and the implications for packaging machinery  
view
Following the accidental death of a toddler, Jonathan Bobbett, Managing Director at Pill protectTM, highlights the need for improvements, in The Countdown Starts for Implementing New Child-Resistant/Senior-Friendly Blister Packaging  
view
In Brand Protection: A Stitch in Time!, Kate Hinsley, Head of Marketing Communications at De La Rue Security Print, argues for improved anti-counterfeiting measures  
view
bullet
Formulations, Ingredients and Excipients
Dr Detlef Wilke, Partner at Biotech Consulting GmbH and Jens A Katzek, Managing Director of BIO-Mitteldeutschland GmbH, consider plants as alternative eukaryotic expression systems, in Primary Production of Biopharmaceuticals in Plants - An Economically Attractive Choice?  
view
In Standardised Extracts and Traditional Herbal Remedies Versus Pharmaceutical Drugs, Andrea Zangara, Research Associate, Jessica Goford, Lead Senior Research Associate and Tamsin Manktelow, Scientific Development Manager at Cognitive Drug Research, discuss the reasons why natural products tend to have less evidence to support their efficacy than commercial drugs  
view
In the near future Britain should become the first country to license a cannabis-based pharmaceutical. David Potter at GW Pharmaceuticals, offers his expertise, in Medicinal Cannabis Production - The Botanist's View  
view
Dr Trevor Theobald, Business Development Director, Indira Walker, Quality and Regulatory Affairs Director and Dr Christopher Stewart, Botanical Sourcing Manager at Kings, examine why every company using plant-based ingredients in their products faces a number of sourcing challenges, in Quality and Risk Management in Botanical Supply Chains  
view
bullet
STERILE MANUFACTURING
New Developments in the Containment of Pharmaceutical Powders are identified and discussed by Martyn Ryder, Managing Director of Extract Technology, part of the Carlisle Life Sciences Group  
view
Richard Paley, Principal Architect and Pharmaceutical Consultant at Bovis Lend Lease, gives an insight into the complex process of cleanroom design, in Designing Biopharma and Pharmaceutical Cleanrooms  
view
bullet
Drug Delivery
Advancements in biotechnology and bioprocessing are driving the rapid development, commercialisation and availability of biopharmaceuticals globally, as explained in Reinventing Biopharmaceutical Manufacturing with Single-Use Disposable Systems, by Carolyn Franceschi, Medical Business Unit Manager at Colder Products Company  
view
Jon Tuckwell, Head of Drug Delivery at Cambridge Consultants, considers the options available to patients in Dry Powder Inhalers - The Best Alternative Drug Delivery Method?  
view
In Taking Nasal Drug Delivery Seriously: Examples of Pain-Free and User-Friendly Alternatives, Pierre Carlotti, Marketing Director at Valois Pharmaceutical Division, explores the direct transport of drugs from the nasal cavity to the central nervous system  
view
bullet
MANUFACTURING
In Manufacturing Hazardous Biologicals: Practical Considerations, Dr Howard S Tranter of the Health Protection Agency assesses why particular attention should be made to assessing the hazards and risks posed to process operator safety during their manufacture  
view
The conservative approach taken to evaluate and qualify water systems used for aseptic pharmaceutical manufacturing, as regulated by the FDA, is discussed by Hank Hicks, Validation Director and David Bosch, Validation Manager, at Pharmaceutical Systems, in Aseptic Pharmaceutical Manufacturing: The Design and Validation of Water for Injection Systems  
view
Adrian Howson, Managing Consultant in Health Care Process Development at PA Consulting Group, identifies key concerns and offers practical solutions, in Why the Health Care Industry Needs a New Approach to Automated Testing  
view
Vertical and Horizontal Integration Offers Supplier Partnerships in Drug Development and Manufacturing - Gerrit van den Dool, Vice President, Europe at Sigma-Aldrich Inc, reflects on the pharma supply industry's transition from being a smaller niche player to a key partner providing a single source of supply
 
view
Risks associated with the operation of isolators, microbials and particulate contamination used for aseptic processing activities are highlighted by Tim Sandle, Microbiologist at Bio Products Laboratory (BPL), in General Considerations for the Risk Assessment of Isolators used for Aseptic Processes  
view
In an interview with Maurice Wolridge, CEO of FAMAR, Patricia Lobo, Editor of PMPS and Senior Consultant at Technomark Consulting Services, asks about The Future of Manufacturing - Is Outsourcing the Solution?  
view
bullet
LOGISTICS
Jamie French, Operations Manager at Biocair, identifies the key issues logistics providers must tackle in order to satisfy client's expectations of more efficient and successful trials, in Clinical Trials - Meeting the Logistics Challenge  
view
According to analysts, the pharmaceutical industry will soon be increasing investments in manufacturing automation and information systems. Edwin Mus, Technical Director at Stevo ICT Tools BV investigates, in the True Benefits of Manufacturing Information Systems through Vast Integration  
view
In Validation - Walk the Talk, Bash Hemani, Managing Director at C4Consulting and Stig Werner, Senior Validation Manager for Europe Pharma Companies, pose the question: does your validation processes measure up?  
view
Peter Van Buren, Sales Director at Introtech bv and Co-Director at Blanken Controls bv, discusses Monitoring Pharmaceuticals During Storing, Handling and Transportation by Means of Indicators  
view
Paul Mayer, Sales Director at Braby, invites you to Take the Hassle Out of Buying a Vessel  
view
In Success Factors for the Cargo Transportation of Pharmaceuticals, PMPS talks to Francis Ramuz, Cool Products Specialist at Swiss WorldCargo  
view
bullet
REVIEW
Is Pharmaceutical Manufacturing now a Contracting Business Proposition? Dr Charles E Horth, Life Science Consulting Editor, reports on the 8th Annual 'Vision in Business' Conference on Contract Manufacturing, 2003  
view
   
spacer
Edited by
Robert Harris
Chief Technical Officer at Juniper Pharma Services
Published quarterly in
February, May,
August and November

News and Press Releases

PSI Conference 2016

2016 PSI Annual Conference at The Pullman Hotel
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was 271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

Industry Events

4th BioLogistics Summit

27-29 June 2016, San Francisco, CA

1 summit for solutions on the storage, handling, and distribution of biologic based products and materials as they are transported.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement